© The Author 2006. Published by Oxford University Press.
EDITORIAL |
Premature Ovarian Failure in Cancer Survivors: New Insights, Looming Concerns
Affiliations of authors: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA (WC); Channing Laboratory (WC) and Division of Preventive Medicine (JEM), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Correspondence to: JoAnn E. Manson, MD, DrPH, Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave. East, Boston, MA 02215 (e-mail: jmanson@rics.bwh.harvard.edu).
| The first 10% of the full text of this article appears below. |
As cure rates for childhood cancers continue to improve, management of long-term consequences of treatment move to the forefront for survivors. Women who undergo cancer treatment before age 21 are at risk for both acute ovarian failure (loss of ovarian function at the time of treatment) and premature ovarian failure (menopause before age 40 in someone with a return of regular menstrual cycles after treatment). Previously, Sklar et al. (1) presented their findings on the incidence and risk factors for acute ovarian failure in the Childhood Cancer Survivor Study Cohort. Here (2), they present their findings on premature ovarian failure. This study improves upon prior ones because it includes detailed information on type and dose of chemotherapy, radiation,